Proton-pump inhibitor (PPI) products based on enteric coated multiparticulates are 21 design to meet the needs of patients who cannot swallow tablets such as children and 22 older adults. Enteric coated PPI preparations exhibit delays in in vivo absorption and 23 onset of antisecretory effects, which is not reflected by the rapid in vitro dissolution in 24 compendial pH 6.8 phosphate buffer commonly used for assessment of these 25 products. A more representative and physiological medium, pH 6.8 mHanks 26 bicarbonate buffer, was used in this study to evaluate the in vitro dissolution of enteric 27 coated multiparticulate-based PPI products. Commercially available omeprazole, 28 lansoprazole and esomeprazole products were subject to dissolution tests using USP-29 II apparatus in pH 4.5 phosphate buffer saline for 45 minutes (acid stage) followed by 30 pH 6.8 phosphate buffer or pH 6.8 mHanks bicarbonate buffer. In pH 6.8 phosphate 31
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buffer, all nine tested products displayed rapid and comparable dissolution profiles 32 meeting the pharmacopeia requirements for delayed release preparations. In pH 6.8 33 mHanks buffer, drug release was delayed and failed the pharmacopeia requirements 34 from most enteric coated preparations. Despite that the same enteric polymer, 35 methacrylic acid -ethyl acrylate copolymer (1:1), was applied to all commercial 36 multiparticulate-based products, marked differences were observed between 37 dissolution profiles of these preparations. The use of pH 6.8 physiological bicarbonate 38 (mHanks) buffer can serve as a useful tool to provide realistic and discriminative in 39
Introduction 46 47
Proton pump inhibitors (PPIs) are highly effective in gastric acid suppression and are 48 increasingly used in the treatment of acid-related disorders such as gastroesophageal 49 reflux disease and peptic ulcer disease (L. S. Welage, 2003) . PPIs are acid-labile 50 compounds; they rapidly degrade at pH levels below 4. Consequently, most PPI 51 products are available as enteric coated (delayed release) dosage forms to protect the 52 active drug in the stomach and release the drug in the small intestine. For patients who 53 cannot swallow conventional tablets such as children and older patients, alternative 54 PPI formulations have been developed including granules in sachets, pellet-enclosed 55 capsules, orally dispersible tablets and MUPS (Multiple-Unit Pellet System) tablets. 56
These formulations are based on the encapsulation of the active compound in enteric 57 coated multiparticulates (granules, pellets, micropellets or microcapsules) of varying 58 sizes. 59
60
Enteric coatings applied to solid dosage forms employ polymers which contain 61 carboxylic acid groups and exhibit pH-dependent dissolution. The dissociation of the 62 enteric polymer and the resultant drug release from coated products in aqueous media 63 are affected not only by the pH of the media but also by their composition and other 64 characteristics, such as the type of buffer species, ionic strength and buffer capacity 65 The enteric coatings applied to PPI products tend to hinder their absorption and delay 79 the onset of antisecretory effect. It can take up to 4 hours for delayed-release PPIs to 80 achieve maximum plasma concentration after oral ingestion (J. R. Horn n/a n/a: not applied 197
198
The buffer capacities of the pH 4.5 phosphate buffer (acid stage), pH 6. The drug release lag times, t80 and release rates (k) are shown in Tables 3 and 4. Drug 220 release from all tested products was immediate (lag times between 5 to 10 minutes) in 221 pH 6.8 phosphate buffer with t80 ranging from 5.8 ± 2.0 to 37.5 ± 6.1 minutes, 222 complying pharmacopoeia requirements (e.g. 80% drug release in 45 minutes as 223 specified in British Pharmacopoeia (British Pharmacopoeia Commission, 2014)). A 224 substantial delay in the onset time of drug release (tlag ranging from 20.8 ± 2.0 to 53.3 225 ± 2.6 minutes) was observed in all tested products in pH 6.8 mHanks buffer. 226
Furthermore, only one product, omeprazole Losec caps, had more than 80% drug 227 release within 45 minutes (t80 44.2 ± 2.0 minutes). All other enteric coated products 228 had less than 80% drug release within 45 minutes (t80 ranging from 45. 56.7 ± 6.1 2.9 ± 0.6 237 238 239 Table 4 . The tlag (minute), t80 (minute) and release rate (% release/minute) from omeprazole products in pH 6.8 phosphate and mHanks buffers. 240
The tlag and t80 are presented as post-acid exposure times (excluding the time period in acid stage). for esomeprazole products (Actavis < Nexium < Emozul) in pH 6.8 mHanks buffer 317 correlated well with their particle sizes (Actavis < Nexium < Emozul); the product 318 with the smallest particle size showed fastest drug release. The rank order was 319 obtained by comparing the drug release onset time between the products. If two 320 products have the same onset time, the release rate was then compared. This 321 relationship between drug release rank order and particle size was not observed for 322 lansoprazole and omeprazole products. The rank order of drug release for omeprazole 323 products is Mezzopram < Losec Caps < Almus < Mepradec (tablet) < Losec MUPS < 324 Actavis, which shows no relationship with the rank order of particle size, Losec 325 MUPS < Mezzopram < Actavis ≈ Losec Caps ≈ Almus < Mepradec (tablet). For 326 lansoprazole products, the brand Zoton showed slowest drug release profile in pH 6.8 327 mHanks buffer despite that it has the smallest particle size. Zoton (lansoprazole) is an 328 oro-dispersible tablet containing gastro-resistant microgranules. The SPC of this 329 product suggests that other than methacrylic acid copolymer a second polymer 330 "polyacrylate dispersion 30 percent" was used for the coating (Datapharm 331
Communications Limited, 2013). Although the grade of the polyacrylate polymer was 332 not specified, it has been reported that ethyl acrylate-methyl methacrylate copolymer 333 30% dispersion (Eudragit to support the design of a meaningful dynamic pH change for testing these products. 467
Therefore, the static pH 6.8 bicarbonate buffer is used in this study and it was able to 468 discriminate between different enteric coated commercial multiparticulate PPI 469 products and revealed their inherent shortcomings of delayed drug release. 470 
